Press release content from Business Wire. The AP news staff was not involved in its creation. Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting February 4, 2021 GMT NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb 4, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021. Two of the abstracts relate to PyL™, the Company’s PET/CT imaging agent for prostate cancer, and the third abstract relates to 1095, the Company’s radiopharmaceutical therapeutic for metastatic castration resistant prostate cancer.